Printer friendly
"AcronymFinder.com

What does CQA stand for?

CQA stands for Critical Quality Attribute

This definition appears somewhat frequently and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.

See other definitions of CQA

Other Resources:
We have 38 other meanings of CQA in our Acronym Attic

Samples in periodicals archive:

Critical quality attributes (CQAs), determined with the patient in mind, have been built into the development process to help ensure quality, safety and efficacy throughout a drug product's lifecycle.
The report covers all aspects of the subject including: * Critical quality attributes * Manufacturing process parameters * Process Analytical Technology * Physicochemical analysis * Bioassays * Formulation and specifications * Product- and process-related impurities * Aggregation * Non-clinical testing * Clinical development, * Post-marketing quality control * Regulatory authority expectations * Risk management * Comparability concerns This unique 300 page report will provide you with the information you need to carve your path through this potential minefield.
The report covers all aspects of the subject including: * Critical quality attributes * Manufacturing process parameters * Process Analytical Technology * Physicochemical analysis * Bioassays * Formulation and specifications * Product- and process-related impurities * Aggregation * Non-clinical testing * Clinical development, * Post-marketing quality control * Regulatory authority expectations * Risk management * Comparability concerns Quality for Biologics is essential reading for corporate management and those in product, process and analytical development, product quality and characterisation, R&D, and regulatory affairs.
The report covers all aspects of the subject including: * Critical quality attributes * Manufacturing process parameters * Process Analytical Technology * Physicochemical analysis * Bioassays * Formulation and specifications * Product- and process-related impurities * Aggregation * Non-clinical testing * Clinical development * Post-marketing quality control * Regulatory authority expectations * Risk management * Comparability concerns The report features contributions from: USB, Lily, Amgen, Roche, NIBSC, Boehringer Ingelheim, Parexel, Probiogen, NIBRT, LFB, Netherlands Medicines Evaluation Board, Paul Ehrlich Institute, and Genentech.